Crossmark

3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Crossref DOI link: https://doi.org/10.1136/bmjno-2024-ANZAN.120

Published Online: 2024-08-16

Published Print: 2024-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Roos, Izanne

Sharmin, Sifat

Malpas, Charles

Lechner-Scott, Jeannette

Hodgkinson, Suzanne

Walt, Anneke Van der

Butzkueven, Helmut

Buzzard, Katherine

Skibina, Olga

John, Nevin

Barnett, Michael

Kalincik, Tomas
License Information

License valid from 2024-08-15